Peregrine Pharma New (PPHM) 0.41 $PPHM Peregrine

New Post Public Reply Private Reply Replies (0) Message Board

Mar 26, 2016 at 1:16 AM

Peregrine Pharma New (PPHM) 0.41 $PPHM

Peregrine Pharmaceuticals (PPHM) Q3 2016 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Mar 09, 10:25AM CST

PPHM: 0.41 (+0.01)

Peregrine Pharma reports FQ3 results
Seeking Alpha - at Seeking Alpha - Wed Mar 09, 8:14AM CST

PPHM: 0.41 (+0.01)

Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments
GlobeNewswire - Wed Mar 09, 7:22AM CST
--Company Focused on Advancing Its Bavituximab Immuno-Oncology Program Through Its Pharmaceutical, Academic and Clinical Collaborations--
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Peregrine reports 3Q loss
Automated Insights - Wed Mar 09, 7:13AM CST
TUSTIN, Calif. (AP) _ Peregrine Pharmaceuticals Inc. (PPHM) on Wednesday reported a loss of $16.8 million in its fiscal third quarter.
PPHM: 0.41 (+0.01)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Mar 08, 4:30PM CST

LGIH: 22.99 (-0.02), EXPR: 20.68 (-0.11), ONCE: 32.43 (-0.45), PPHM: 0.41 (+0.01), VRA: 19.76 (+1.14), AMED: 43.76 (+0.01), KFY: 28.00 (-0.43), HOV: 1.46 (-0.04), LMIA: 8.98 (+0.12)

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
GlobeNewswire - Mon Mar 07, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (Nasdaq

PHM) (Nasdaq

PHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock"

.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility
GlobeNewswire - Mon Mar 07, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that its new state-of-the-art commercial biomanufacturing suite in Tustin, California, has been formally commissioned. As part of the commissioning process, all relevant regulatory agencies have been notified and cGMP production is currently underway. The new Peregrine facility, which is being operated by Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine, will more than double the company's prior manufacturing capacity, supporting up to an additional $40 million in revenue each year.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
GlobeNewswire - Thu Mar 03, 3:05PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the third quarter of fiscal year 2016 ended January 31, 2016 on March 9, 2016 prior to market open and will host a conference call and webcast at 8:30 AM Pacific Time (11:30 AM Eastern Time). Peregrine's senior management will discuss financial results for the third quarter and review the recent progress of its clinical development programs.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

OncBioMune Patents a New Promising Approach to Chemotherapy
ACCESSWIRE - Thu Jan 28, 7:00AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both cancerous and normal cells. In order to solve this problem, researchers have tried a number of different approaches. The most common approach has been conjugating anti-cancer agents to antibodies or functional fragments, but even then, there are significant numbers of normal cells affected.
SGEN: 34.68 (+0.09), IMGN: 7.85 (+0.04), PPHM: 0.41 (+0.01), SRNE: 4.98 (+0.04), CELG: 100.54 (+0.62)

Peregrine Pharma (PPHM): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 7:43AM CST
Peregrine Pharma is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
PPHM: 0.41 (+0.01)

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences
GlobeNewswire - Wed Jan 20, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that members of the company's scientific team will deliver podium presentations focused on the role of combination immunotherapies in the treatment of cancer at two upcoming immunotherapy conferences. Jeff T. Hutchins, Ph.D., Peregrine's vice president, preclinical research, will speak at Immunotherapy World 2016, being held January 25-27, 2016 in Washington, D.C. Additionally, Bruce Freimark, Ph.D., research director, preclinical oncology at Peregrine, will present at GTCBio's 8th Immunotherapeutics & Immunomonitoring Conference, being held January 25-26, 2016 in San Diego, CA.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
GlobeNewswire - Mon Jan 11, 7:05AM CST
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 --
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Peregrine (PPHM) Inks Research Partnership for Bavituximab
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:00PM CST
Peregrine (PPHM) is collaborating with the National Comprehensive Cancer Network to evaluate bavituximab for the treatment of a range of tumors.
AZN: 28.00 (-0.01), HZNP: 16.02 (-0.30), PPHM: 0.41 (+0.01), SNY: 38.87 (-0.53)

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
GlobeNewswire - Wed Jan 06, 7:05AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ

PHM) (NASDAQ

PHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced a new research collaboration with the National Comprehensive Cancer Network(R) (NCCN(R)) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors. NCCN, a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN's Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
PPHMP: 17.99 (+0.15), PPHM: 0.41 (+0.01)

Surging Earnings Estimates Signal Good News for Peregrine Pharmaceuticals (PPHM)
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 7:46AM CST
Peregrine Pharmaceuticals has decent short-term momentum and is also seeing solid activity on the earnings estimate revision front as well.
PPHM: 0.41 (+0.01)

The Life Sciences Report Announces 19 Companies for the 2016 Small-Cap Biotech Watchlist
Marketwired - Tue Dec 22, 8:01AM CST
In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.
CRMD: 2.38 (+0.02), PIRS: 1.93 (+0.17), AST: 4.57 (-0.08), PPHM: 0.41 (+0.01)

Why You Shouldn't Bet Against Peregrine Pharmaceuticals (PPHM) Stock
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 7:39AM CST
Peregrine Pharmaceuticals (PPHM) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PPHM: 0.41 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

See's Candies Data Breach Spurs Legal Scrutiny

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Ice-Rock Avalanches: Future Risks and Urgent Lessons

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

China Hour Expands Chinese Media Footprint in Africa

An Ambitious Cross-Continental Media Play The airwaves are getting a new twist. This time, it's a blend of cultures, as China Hour makes an entrance in South Africa. That's right, folks—Jiangsu Broadcasting Corporation (JSBC) has set up camp alongside the South African Broadcasting Corporation (SABC), pushing a big media wave across the continent. If you've been...

Auto Maintenance: Key Tips for Long-Term Vehicle Health

Beating Breakdown Blues: Preventative Maintenance Insights You ever look under the hood and wonder what's ticking away? Cars ain't just about turning keys and hitting gas—there's a beating heart under all that metal and rubber. That's what HelloNation's serving us here, with David Mantz and his kid, David Mantz Jr., lifting the lid on preventative maintenance. These...

Softcare Facilitates Standards Delegation Visit to Senegal

Ever seen a whole nation's hygiene industry getting a deep dive from not just one, but three major standards bodies? That's what just went down in Senegal. Softcare opened its doors wide to folks from the Senegalese Association for Standardization (ASN), the International Organization for Standardization (ISO), and the Swedish Institute for Standards (SIS). This was no...

MERACH Unveils W60 Plus: A Game Changer for Home Fitness

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Creality Rolls Out K3, SPARKX i8 at IFA 2026

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Roborock Fuels Market Surge with 27.6% Revenue Boost

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Mermaid Folklore Meets Revolution in New Short Film

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...